Evidence map›Paper›PMID 32256938›Full record

ArticleCurrent fungal infection reports2020

Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?

Matthew A Miller, Yee Ming Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current fungal infection reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Antifungals: From Pharmacokinetics to Clinical Practice.Antibiotics (Basel, Switzerland) · 2023
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew A MillerDepartment of Pharmacy Services, University of Colorado Hospital, Aurora, CO, USA.
Yee Ming LeeDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 E Montview Blvd, Mail Stop C238, Aurora, CO 80045, USA.

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR002535
6 · The paper itself

Abstract

purpose of reviewThis review summarizes recent literature for applying pharmacogenomics to antifungal selection and dosing, providing an approach to implementing antifungal pharmacogenomics in clinical practice. RECENT

findingsThe Clinical Pharmacogenetics Implementation Consortium published guidelines on SUMMARY: Sufficient evidence is available for implementing

Indexed as

AntifungalCYP2C19DosingInvasive fungal diseasePharmacogenomicsVoriconazole

Identifiers

PMID32256938
PMCPMC7111498

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.